| Mrs Jomarie Lozada Rivera, REGISTER NURSE | |
|
B7 Calle Tabonuco, Guaynabo, PR 00968-3342 | |
| (787) 792-2144 | |
| Not Available |
| Full Name | Mrs Jomarie Lozada Rivera |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Medical-surgical |
| Location | B7 Calle Tabonuco, Guaynabo, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588321632 | NPI | - | NPPES |
| 9450304 | Medicaid | FL | |
| 3241E | Medicaid | PR |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Jomarie Lozada Rivera, REGISTER NURSE B7 Calle Tabonuco Ste 301, Guaynabo, PR 00968-3364 Ph: (787) 792-2144 | Mrs Jomarie Lozada Rivera, REGISTER NURSE B7 Calle Tabonuco, Guaynabo, PR 00968-3342 Ph: (787) 792-2144 |
News Archive
Although traumatic brain injury (TBI) is one of the leading causes of death in the United States, work-related TBI has not been well documented. In a study published in the July issue of the American Journal of Preventive Medicine, researchers describe the epidemiology of fatal TBI in the US workplace between 2003 and 2008.
McMaster University researchers who analyzed thousands of documents covering a 300-year span of plague outbreaks in London, England, have estimated that the disease spread four times faster in the 17th century than it had in the 14th century.
As the month of November kicks off PH Awareness Month, Dr. Ronald Oudiz - lead investigator at the Los Angeles Biomedical Research Institute (LA BioMed) - hopes to bring greater awareness to this disorder that has affected the lives of so many. Dr. Oudiz is a pioneer in this field, having received the 2011 Award for Excellence earlier this year from the Pulmonary Hypertension Association for his dedication to find new ways to treat this often fatal disease.
C. R. Bard, Inc. today announced that it has reached a definitive agreement to acquire SenoRx, Inc. (Nasdaq: SENO), for a purchase price of $11.00 per share in cash, totaling approximately $200 million, net of cash acquired.
› Verified 4 days ago